Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia. Using next-generation sequencing technology (NGS), ...
Jun 7, 2016
0
3
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since ...
May 2, 2016
0
2
Manchester scientists have identified a potential double drug combination against B-cell acute lymphoblastic leukaemia, according to a study published in the journal Cell Death and Disease today.
Apr 8, 2016
0
14
Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly ...
Mar 16, 2016
0
2
A technique called "mito-priming" is the latest method to be developed by researchers in the fight against cancer.
Feb 3, 2016
0
8
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
Jan 6, 2016
0
3
Genes that act as brakes to stop the development of an aggressive form of leukaemia have been identified by researchers.
Dec 7, 2015
0
2
Researchers have identified a genetic fault in some leukaemia patients that could be responsible for halving survival times after diagnosis compared to patients without the fault – an average reduction from 16 years to ...
Dec 7, 2015
0
0
The report, 'Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates' by colleagues at Melbourne and Adelaide universities, has passed peer review on F1000Research.
Nov 25, 2015
0
3
The latest case report published in ecancermedicalscience describes the case of a woman who had the double burdens of chronic leukaemia and an unplanned pregnancy - and her happy outcome.
Nov 13, 2015
0
11
